Navigation Links
Gliknik Enters Into Licensing Agreement With Pfizer For Drug Candidate Targeting Autoimmune Diseases
Date:9/30/2013

BALTIMORE, Sept. 30, 2013 /PRNewswire/ -- Gliknik Inc., a privately held biopharmaceutical company, today announced that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. for GL-2045, Gliknik's recombinant stradomer™, a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). GL-2045 has shown promising results in a broad range of preclinical tests and is being developed as a potential treatment for a wide variety of autoimmune diseases, including those in which IVIG is clinically used.

"GL-2045 is the first of several innovative drug candidates Gliknik is advancing for people with autoimmune diseases and cancer," said Gliknik CEO David S. Block. "We selected Pfizer as our partner to progress GL-2045 from among several interested and capable parties because of its exceptional development, manufacturing and commercial capabilities."

Under the terms of the license agreement, Pfizer will receive an exclusive worldwide license to GL-2045 for all therapeutic indications. Gliknik will receive an upfront payment of $25 million and is eligible to receive development, regulatory and commercial milestone payments. Gliknik is also eligible to receive tiered, double-digit royalties on net sales of any products that are commercialized pursuant to this license agreement.

"People with certain autoimmune diseases have limited treatment options, difficult regimens and often a poor prognosis," said Jose Carlos Gutierrez-Ramos, Ph.D., group senior vice president and head of Biotherapeutics R&D at Pfizer. "Pooled IVIG has a long history of use but has a number of limitations. We are pleased to partner with Gliknik on this novel therapeutic approach which may provide an important new option in managing debilitating autoimmune diseases."

About GL-2045

GL-2045 is Gliknik's lead preclinical recombinant stradomer™ for autoimmune diseases. It has demonstrated potent efficacy in numerous preclinical tests and is in IND-enabling manufacturing. GL-2045 acts by presenting highly ordered multimers of normal human IgG Fc to its receptors.

About Gliknik Inc.

Founded in 2007, Gliknik is a biopharmaceutical company creating new therapies for patients with cancer and immune disorders. Gliknik's expertise is in modulation of the immune system to fight disease. Gliknik's lead clinical compound is the immune modulator GL-0817 for cancer, which is poised to enter Phase IIb clinical studies. Learn more at www.gliknik.com.

This press release contains "forward-looking statements" concerning the development and commercialization of GL-2045 and other Gliknik products, the potential benefits and attributes of such products, and the possible receipt by Gliknik of future payments. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Gliknik undertakes no obligation to update any forward-looking statements for any reason.


'/>"/>
SOURCE Gliknik Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Gliknik Adds Incyte President & CEO Paul A. Friedman to its Board of Directors
2. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
3. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
4. CyberKnife System and the da Vinci Surgical System in Concord Medical Centers Achieve Over RMB 10 Million in Medical Revenue Since Opening in February
5. 3 Pediatric Centers that Offer SynCardia Total Artificial Heart Named in Top 10 for "Best Childrens Hospitals"
6. Abaxis Enters Into Definitive Agreement To Deliver 300 Piccolo Xpress Instruments For A Four-Year Drug Clinical Trial
7. The Galien Foundation Announces Roster of Luminary Presenters for Third Galien Forum; Program Highlights Include CEO Panel, Panel on Alzheimers Disease Innovation, Nobel Laureate Elie Wiesel
8. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
9. Spine Pain Management Opens Two Additional Affiliate Diagnostic Centers in Florida
10. Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
11. CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
(Date:9/18/2017)... , Sept. 18, 2017  PMD Healthcare of ... Pharmacy of Kalamazoo, Mich. , have ... service that expedites and streamlines patient and provider access ... 2.0, and wellness management services.  ... used to measure lung function for a variety of ...
(Date:9/13/2017)... , Sept. 13, 2017   OrthoAtlanta has been ... Atlanta Football Host Committee (AFHC) for the 2018 College Football ... 8, 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... the AFHC "I,m In" campaign, participating in many activities leading ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
Breaking Medicine News(10 mins):